06 Prognostic factors for survival and recurrence in adult medulloblastoma

BACKGROUND: Adult medulloblastomas account for less than 1% of adult neoplasms. They are challenging to treat due to their rarity and the heterogeneity of treatment options, all of which have limited evidence. In this retrospective review, we examined cases of adult medulloblastoma diagnosed in Albe...

Full description

Saved in:
Bibliographic Details
Published in:Canadian journal of neurological sciences 2018-06, Vol.45 (S3), p.S1-S1
Main Authors: Yusuf, D., Krauze, A., Easaw, J., Murtha, A., Amanie, J., Roa, W., Ghosh, S., Eisenstat, D., Patel, S.
Format: Article
Language:English
Subjects:
10 MAY 2018 @ 1800-1900: 11 MAY 2018 @ 1620-1720: 12 MAY 2018 @ 1010-1035
Chemotherapy
Medical prognosis
POSTER VIEWING SESSIONS
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND: Adult medulloblastomas account for less than 1% of adult neoplasms. They are challenging to treat due to their rarity and the heterogeneity of treatment options, all of which have limited evidence. In this retrospective review, we examined cases of adult medulloblastoma diagnosed in Alberta during a 70-year period. METHODS: We reviewed the charts of patients diagnosed with medulloblastoma between 1944 and 2014. We performed Cox and logistic regression analysis to elucidate features that may influence recurrence risk and survival. RESULTS: We found 86 and analyzed 78 cases. The median age at diagnosis was 27 (range 16 to 71). Most were male (68%). Most had surgery (92%). By COG risk stratification, 54% were standard risk while 21% were poor risk. RT was administered to 85% of patients, and craniospinal irradiation (CSI) to 81%. Chemotherapy was administered to 48%. Median survival was 4.4 years from diagnosis (range 0 to 20). At last follow-up, 39% were alive and recurrence-free. Patients who had CSI and posterior fossa boost had longer survival (p=0.047 and
ISSN:0317-1671
2057-0155
DOI:10.1017/cjn.2018.254